Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synthetic MR ABLTS:0G79 63 Return-on-Tangible-Equity is -60.14% as of Mar. 2026. GuruFocus rates LTS:0G79 with a GF Score™ of 63/100 and a GF Value™ of kr122.54. The stock has 3 warning signs investors should review. Among 581 Healthcare Providers & Services companies, Synthetic MR AB ranks worse than 92.6% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Synthetic MR AB's annualized net income for the quarter that ended in Mar. 2026 was kr-24.75 Mil. Synthetic MR AB's average shareholder tangible equity for the quarter that ended in Mar. 2026 was kr41.15 Mil. Therefore, Synthetic MR AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -60.14%.
The historical rank and industry rank for Synthetic MR AB's Return-on-Tangible-Equity or its related term are showing as below:
LTS:0G79'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -105.86 Med: 10.51 Max: 46.46
Current: -105.86
During the past 13 years, Synthetic MR AB's highest Return-on-Tangible-Equity was 46.46%. The lowest was -105.86%. And the median was 10.51%.
LTS:0G79's Return-on-Tangible-Equity is ranked worse than 92.6% of 581
companies
in the Healthcare Providers & Services industry
Industry Median: 10.13
vs LTS:0G79: -105.86
Synthetic MR AB (LTS:0G79) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Synthetic MR AB Return-on-Tangible-Equity Related Terms
Synthetic MR AB Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Synthetic MR AB's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0G79 vs VEEV, BTSG, TEM: Return-on-Tangible-Equity Comparison
For the Health Information Services subindustry, Synthetic MR AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synthetic MR AB Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Synthetic MR AB's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Synthetic MR AB's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -60.14% mean?
Synthetic MR AB (LTS:0G79) has a Return-on-Tangible-Equity of -60.14% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Synthetic MR AB and its competitors. According to the industry distribution chart, Synthetic MR AB ranks #538 out of 581 companies in the Healthcare Providers & Services industry, placing it in the top 92.6%.
Is Synthetic MR AB's Return-on-Tangible-Equity too high?
Synthetic MR AB's current Return-on-Tangible-Equity is -60.14%. Based on the distribution chart, Synthetic MR AB ranks #538 out of 581 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Synthetic MR AB has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Synthetic MR AB's Return-on-Tangible-Equity compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Synthetic MR AB ranks #538 out of 581 companies for Return-on-Tangible-Equity. This places Synthetic MR AB in the lower half of its industry. The industry median Return-on-Tangible-Equity is 10.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.13, based on 581 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Synthetic MR AB and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synthetic MR AB's current Return-on-Tangible-Equity is -60.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synthetic MR AB stock overvalued right now?
Synthetic MR AB (LTS:0G79) has a current Return-on-Tangible-Equity of -60.14%. The stock's GF Value™ is kr122.54, compared to a current price of kr16.23 — trading 86.8% below its estimated fair value. The current Return-on-Tangible-Equity is -60.14%. Synthetic MR AB's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Synthetic MR AB (LTS:0G79), the current Return-on-Tangible-Equity is -60.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synthetic MR AB (LTS:0G79) Overvalued in 2026?
Based on GuruFocus' analysis, Synthetic MR AB stock appears to be undervalued.
The current stock price of kr16.23 is trading 86.8% below its estimated GF Value™ of kr122.54.
Key valuation signals for LTS:0G79:
Return-on-Tangible-Equity: -60.14%
GF Value™: kr122.54 vs. price of kr16.23 (86.8% below fair value)
No single metric tells the full story. See the LTS:0G79 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synthetic MR AB develops and markets software solutions that improve the efficiency of neuroimaging processes and diagnostic accuracy. SyntheticMR's SyMRI solution measures the brain's absolute tissue properties and generates multiple contrast-weighted images, performs automatic segmentation of biomarkers, and delivers quantitative data in a single rapid examination. Combinostics offers the AI-driven cNeuro product family, which helps clinicians make a difference in the lives of patients with neurological diseases. Geographically, the group operates in America, Europe, and APAC. The majority of its revenue is generated from Europe.
63GF Score
Get the complete analysis for LTS:0G79
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0G79 has been successfully added to your 
